Gabapentin Dosing for Sciatica
Start gabapentin at 100-300 mg at bedtime or 100-300 mg three times daily, then increase by 100-300 mg every 1-7 days as tolerated, targeting 1800-3600 mg/day in three divided doses, though evidence for gabapentin's effectiveness specifically in sciatica is weak and conflicting. 1, 2
Critical Evidence Gap
The most important caveat: gabapentin lacks robust evidence for sciatica specifically. A 2022 systematic review and meta-analysis found clear evidence for lack of effectiveness of gabapentin for sciatica pain management, concluding its routine clinical use cannot be supported 3. Another 2026 umbrella review found controversial results for gabapentinoids in various neuropathic conditions, with most studies being critically low quality 4.
Dosing Algorithm (If You Choose to Prescribe)
Starting Dose
- Day 1: 100-300 mg at bedtime OR 100-300 mg three times daily 1, 2
- Lower starting doses (100 mg) reduce initial side effects like dizziness and sedation
Titration Schedule
- Increase by 100-300 mg every 1-7 days as tolerated 1
- The FDA label for postherpetic neuralgia suggests: 300 mg Day 1,600 mg/day Day 2,900 mg/day Day 3 2
- For sciatica, slower titration may improve tolerability
Target Dose
- 1800 mg/day (600 mg three times daily) is the evidence-based target for neuropathic pain 1, 2
- Maximum: 3600 mg/day in three divided doses 1, 2
- Maximum 12-hour interval between doses 2
Duration of Adequate Trial
- 3-8 weeks for titration PLUS 2 weeks at maximum tolerated dose 1
- An adequate trial can require 2 months or more 1
Special Populations
Renal Impairment
Dose reduction is mandatory based on creatinine clearance 1, 2:
- CrCl ≥60 mL/min: 900-3600 mg/day (300-1200 mg TID)
- CrCl 30-59 mL/min: 400-1400 mg/day (200-700 mg BID)
- CrCl 15-29 mL/min: 200-700 mg/day (200-700 mg once daily)
- CrCl <15 mL/min: 100-300 mg once daily
- Hemodialysis: Maintenance dose based on CrCl + supplemental 125-350 mg post-dialysis 2
Elderly Patients
- Use lower starting doses and slower titration 1, 2
- Elderly patients have higher risk of decreased renal function requiring dose adjustment 2
Comparative Evidence
Gabapentin vs. Pregabalin: One 2019 head-to-head RCT in chronic sciatica (n=18) found gabapentin superior to pregabalin with fewer and less severe adverse events 5. Gabapentin showed greater pain reduction (VAS reduction 1.72 vs 0.94, p=0.035), though both drugs significantly reduced pain. However, this was a small study.
Gabapentin vs. Placebo for Radicular Pain: A 2017 systematic review for the American College of Physicians found inconsistent evidence for gabapentin in chronic radicular back pain, with effects ranging from 0.3 to 1.9 points on a 0-10 scale across three poor-quality trials 6.
Common Pitfalls
Nonlinear pharmacokinetics: Gabapentin has saturable absorption, requiring careful dose titration rather than rapid escalation 1
Premature discontinuation: Patients may stop before reaching therapeutic doses due to initial side effects (dizziness, sedation). Starting low and titrating slowly improves tolerability 1
Inadequate trial duration: Stopping before 2 months at adequate doses may miss potential responders 1
Ignoring renal function: Failure to adjust for renal impairment increases toxicity risk 1, 2
Abrupt discontinuation: Taper over minimum 1 week when stopping 2
Clinical Reality
Given the lack of evidence for sciatica specifically, consider gabapentin only after failure of first-line treatments (NSAIDs, physical therapy, time for natural resolution). The 2017 ACP guideline found antiseizure medications showed no benefit for chronic nonradicular back pain and inconsistent results for radicular pain 6. The most recent systematic review explicitly states gabapentin's routine use for sciatica cannot be supported 3.
If prescribing despite weak evidence, use the neuropathic pain dosing algorithm above, recognizing you're extrapolating from conditions like postherpetic neuralgia and diabetic neuropathy where evidence is stronger 2.